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Abstract
While advanced melanoma remains one of the most challenging cancers, recent developments in our understanding of the
molecular drivers of this disease have uncovered exciting opportunities to guide personalized therapeutic decisions.
Genetic analyses of melanoma have uncovered several key molecular pathways that are involved in disease onset and
progression, as well as prognosis. These advances now make it possible to create a ‘‘Molecular Disease Model’’ (MDM) for
melanoma that classifies individual tumors into molecular subtypes (in contrast to traditional histological subtypes), with
proposed treatment guidelines for each subtype including specific assays, drugs, and clinical trials. This paper describes
such a Melanoma Molecular Disease Model reflecting the latest scientific, clinical, and technological advances.
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Introduction
Melanoma is the most aggressive form of skin cancer and its
incidence is on the rise worldwide [1]. While early stages of mela-
noma can be successfully treated by surgical excision, advanced
stages are uniquely refractory to current therapies. However, we
now recognize that melanomas are far more variable at a mole-
cular level than they appear under the microscope. Therefore,
rather than treating melanoma as a single disease, it makes sense to
stratify tumors into molecular subtypes and treat each with the
most appropriate therapies. This approach is supported by the
dramatic success of PLX4032 for melanoma tumors possessing the
BRAF V600E mutation [2], and Imatinib for those possessing
C-KIT mutations [3–5].
With hundreds of molecular diagnostics and targeted therapies
in development, the time is ripe to develop a formal process for
classifying melanoma into molecular subtypes, and for developing
proposed treatment guidelines for each subtype, including specific
assays, drugs, and clinical trials. This process produces a formal
’Molecular Disease Model’ (MDM) that can be used by clinicians
to guide treatment decisions, and refined by researchers based on
clinical outcomes and laboratory findings.
This paper outlines such a Molecular Disease Model for
melanoma. The model consists of a set of actionable molecular
subtypes and proposed practice guidelines for treating each
subtype: which therapies (approved or experimental) should be
considered and which are contraindicated (see Tables 1 and 2). A
molecular subtype of melanoma is loosely defined as those tumors
containing the same set of molecular (primarily genetic) defect(s)
and their associated pathways (see Figure 1). A subtype is deemed
actionable if there is both a CLIA-approved assay to determine
whether a given tumor fits that classification, and at least one
FDA-approved or experimental targeted therapy with potential
efficacy for that subtype. An example would be melanoma tumors
containing a BRAF V600E mutation for which commercial assays
and targeted agents are currently available. The latest version
of the Melanoma Molecular Disease Model can be found
online here: http://mmdm.cancercommons.org/smw/index.php/
A_Melanoma_Molecular_Disease_Model.
The online version contains additional in-depth information
about relevant genes, genetic tests, pathways, drugs, targets, and
clinical trials, all hyperlinked and organized in a Wikipedia-like
format. Given the evolving state of knowledge, we anticipate that
this baseline model will need to be revised with new clinical and
scientific findings. Existing types are likely to be split into new
subtypes corresponding to responders and non-responders,and new
types are likely to be added to accommodate previously unseen
tumor types. Over time, this model will be defined with greater and
greater specificity and linked to increasingly efficacious therapies.
Methods
The initial subtypes and associated practice guidelines defined
herewereidentifiedbyconsensusofapanelofrecognizedmelanoma
experts, and supported by detailed analysis of the peer-reviewed
scientific literature. Subtypes are defined based on the status of key
melanoma genes/pathways and their combinations. Each subtype is
defined by one key oncogene/tumor suppressor (such as BRAF for
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combination with others that play a supportive role (such as PTEN,
AKT and CDK4 in the case of subtypes 1.2, 1.3 and 1.4).
Results
Tables 1 and 2 summarize the types of melanoma, roughly in
order of importance of the associated oncogene/tumor suppressor,
prevalence and potential for therapeutic intervention. We believe
that the oncogenes that define the subtypes in Table 1 are capable
of serving as the dominant oncogene and putative point of
intervention for therapy, whereas the oncogenes and tumor
suppressor genes that define subtypes in Table 2 play a supportive
role and typically co-exist with the mutations outlined in Table 1.
Table S1 provides the drugs, their manufacturer and their
putative targets for each subtype, as well as the relevant clinical
trials and their status. It is our hope that the present model serves
to focus translational research on issues that may directly impact
patient care, and that the resulting activity will lead to updates in
the model. For example, melanomas that fit into one of these
subtypes, but which do not respond as predicted, may necessitate
splitting of that subtype in a future revision of the model.
Subtype 1
Subtype 1 harbors aberrations in the MAPK (Mitogen-activated
protein kinase) pathway, either by itself or in combination with
others such as the AKT/PI3K and CDK pathways. The MAPK
pathway is a phosphorylation-driven signal transduction cascade
that couples intracellular responses to the binding of growth
factors to cell surface receptors. This pathway regulates several
processes including cell proliferation and differentiation, and is
often dysregulated in a variety of cancers. The classical MAPK
pathway consists of RAS, RAF, MEK and ERK, where RAS
triggers the formation of a RAF/MEK/ERK kinase complex
which then drives transcription of key regulators through protein
phosphorylation. Each of these components is encoded by several
genes that play subtly distinct roles in signal transduction. For
example, the RAF kinase family consists of three members: ARAF,
BRAF and CRAF each of which can activate MEK/ERK
signaling [6]. Molecular tests associated with subtypes 1.1–1.4
include: BRAF targeted sequencing for the presence of V600E
mutation, Immuno-Histo-Chemical (IHC) tests for reduced PTEN
protein levels, tests examining increased copy number of AKT,
and IHC indicating increased CCND1/Cyclin D protein levels.
Subtype 1.1 overview
Subtype 1.1 is characterized by a mutation in the BRAF gene.
BRAF encodes a serine/threonine-protein kinase and is the most
commonly mutated gene in melanoma (observed to be mutated
in 40–70% of melanoma) [7]. While .60 mutations have been
mapped in BRAF, a valine to glutamic acid change at codon 600
(V600E) occurs in .90% of cases. This mutation leads to
Table 1. Principal melanoma molecular subtypes.
Detailed
subtypes Pathway(s)
Key gene /
biomarker(s) Diagnostic technologies Potentially relevant therapeutics
1.1 MAPK BRAF Targeted sequencing BRAF inhibitors, MEK inhibitors, Hsp90 inhibitors
1.2 BRAF/PTEN Targeted sequencing & IHC (BRAF inhibitors) AND (PI3K inhibitors, AKT inhibitors or mTOR inhibitors)
1.3 BRAF/AKT Targeted sequencing & copy
number
(BRAF inhibitors) AND (AKT inhibitors or mTOR inhibitors)
1.4 BRAF/CDK4 Targeted sequencing & copy
number/CGH
BRAF inhibitors
AND CDK inhibitors
2.1 c-KIT c-KIT Targeted sequencing Gleevec & other c-KIT inhibitors
3.1 GNAQ GNA11 GNAQ Targeted sequencing MEK inhibitors
3.2 GNA11 Targeted sequencing MEK inhibitors
4.1 NRAS NRAS Targeted sequencing MAPK & PI3K pathway inhibitors; Farnesyl transferase inhibitors
5.1 MITF MITF Copy number HDAC inhibitors
doi:10.1371/journal.pone.0018257.t001
Table 2. Secondary melanoma molecular subtypes.
Detailed
subtypes Pathway(s)
Key gene /
biomarker(s) Diagnostic technologies Potentially relevant therapeutics
6.1 AKT/PI3K PTEN IHC PI3K inhibitors, AKT inhibitors or mTOR inhibitors
6.2 AKT Copy number AKT inhibitors or mTOR inhibitors
6.3 PI3K IHC PI3K inhibitors, AKT inhibitors or mTOR inhibitors
7.1 CDK ARF/INK4A Targeted sequencing / CGH CDK inhibitors
7.2 CDK4 Copy number / CGH CDK inhibitors
7.3 CCND1 / Cyclin D1 Copy number / CGH CDK inhibitors
8.1 P53 / BCL Bcl-2 IHC TBD
8.2 P53 Targeted sequencing TBD
doi:10.1371/journal.pone.0018257.t002
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activation by NRAS and ATP. In addition, this mutant protein
is .10-fold more active than wildtype BRAF. Taken together,
these data indicate the importance of BRAF as a therapeutic target
in melanoma. In some melanomas, BRAF mutations occur along
with other mutations in genes such as PTEN and CDK4. These
double mutant combinations are described below. However, since
melanomas are not routinely screened for these genes, some
melanomas that belong to these subtypes may be mis-classified
as 1.1.
Potential therapeutic approach for subtype 1.1
There are several potential targets for therapeutic intervention
in this pathway including BRAF, MEK, ERK and Hsp90. Drugs
targeting BRAF, MEK, and Hsp90 (but not ERK) are in
development, and clinical trials are ongoing to evaluate their
efficacy in melanoma.
BRAF inhibitors
The BRAF inhibitor, Sorafenib/Nexavar, was the first RAF
kinase inhibitor to be tested in humans. It is a broad RAF kinase
inhibitor that competes with ATP for binding to RAF. Sorafenib
suppresses BRAF as well as CRAF with similar efficiency by
stabilizing the inactive conformations, though it is less efficacious
on the BRAF V600E form than on wildtype. Sorafenib failed to
demonstrate efficacy against melanoma by itself but may be
somewhat effective with chemotherapy, albeit independently of
BRAF status.
Several second generation inhibitors with greater specificity
than Sorafenib are in development and one of these, PLX4032,
appears very promising. This drug is highly specific for the V600E
version of BRAF. Results of a Phase I study announced in 2009 at
ASCO’s annual conference indicated a response in almost 80% of
participants and tumor shrinkage was observed in nearly all
patients [8]. Further testing is ongoing in patients with the BRAF
V600E mutation.
Another exciting inhibitor of BRAF V600E is GSK2118436
which is a highly potent and selective ATP competitive BRAF
inhibitor with .100-fold selectivity for mutant (mut) BRAF over
wild type (wt) in cell lines. In a Phase I/II, clinical activity with
minimal toxicity was observed at multiple dose levels in mutant
BRAF tumors [9]. Arguably the most exciting characteristic of this
drug is its potential to control brain metastases in melanoma
patients, which are notoriously resistant to drug therapy. Of 10
trial participants with previously untreated brain metastases, all
experienced control of melanoma brain metastases, and 9 of the
10 patients had reductions in the overall size of their brain
metastases [10].
Other selective BRAF inhibitors in clinical testing include
RAF265 (an inhibitor of ARAF, CRAF and mutant & wildtype
BRAF) and XL281 (an inhibitor of CRAF and both wildtype and
V600E BRAF). Results of a Phase I study of XL281 presented at
ASCO’s annual conference in 2009 showed clinical benefit in 43%
of enrollees [11], however, some systemic toxicity was noticed that
could hamper its treatment potential. RAF265 is currently being
evaluated in the Phase I setting for melanoma.
While there is great hope that these drugs will successfully halt
progress in patients with BRAF mutant melanomas, emerging data
suggests that they might be counterproductive for patients with
wildtype BRAF. Treatment of BRAF-wildtype cells with these
Figure 1. The two major signaling pathways implicated in melanoma are the MAPK pathway (red) and the AKT/PI3K (green) pathway
which regulate cell growth, proliferation and cell death. There is a lot of cross-talk between these pathways and their downstream effectors,
which we have classified into 8 pathways for simplicity to account for differences in treatment modalities (e.g. signaling through NRAS could affect both
MAPK and AKT/PI3K pathways). The additional 6 pathways are: c-KIT (pink), CDK (blue), GNAQ/GNA11 (brown), MITF (orange), NRAS (yellow), and P53/
BCL (purple). The complex relationship among BRAF, ARF/INK4A (via dashed line), p16, and p14ARF connotes an alternative splicing relationship.
doi:10.1371/journal.pone.0018257.g001
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mechanisms [12–14]. These results suggest that PLX4032 and
others might be indicated only for patients whose tumors harbor
activating mutations in BRAF.
MEK inhibitors
The MEK inhibitor, AZD6244/ARRY-142886, is an ATP
non-competitive, allosteric inhibitor of MEK1/MEK2. In a Phase
II trial in melanoma, AZD6244 did not appear superior as
compared to temozolomide. However, this trial was not restricted
to patients with BRAF mutations [15]. Current studies in progress
are selecting for patients based on their BRAF status. Another
MEK1/2 inhibitor, GSK1120212, is in Phase II for BRAF-mutant
melanoma as well as for melanomas with GNAQ and GNA11
mutations. Several others are also in Phases I and II for advanced
malignancies and tumors.
Hsp90 inhibitors
Hsp90 is a molecular chaperone that drives folding and
stabilization of various cellular proteins, including BRAF. Hsp90
has preferential activity towards activated BRAF as compared to
normal BRAF [16]. In addition, pharmacological inhibition of
Hsp90 function results in degradation of activated BRAF,
inhibition of MAPK activity and cell proliferation, and induction
of apoptosis [17]. Several Hsp90 inhibitors are currently
undergoing clinical investigation for melanoma.
Subtypes 1.2 & 1.3 overview
These subtypes are characterized by abnormalities in both the
MAPK and AKT/PI3K pathways. While current treatments and
drug development programs are mostly centered on individual
mutations and pathways, there is increasing evidence suggesting
that melanoma requires multiple pathways for development and
metastasis. The most widespread collaboration appears to be
between the AKT/PI3K and MAPK pathways, specifically: 1.
BRAF mutations are often accompanied by loss of PTEN or
activation of AKT [18–19], 2. PTEN silencing is required for
malignant transformation of BRAF-mutant melanoctyes in a
mouse model [20], and 3. pharmacological inhibition of both, but
not individual, pathways is highly effective in suppressing
melanoma disease in pre-clinical models [21–25].
Potential therapeutic approach for subtypes 1.2 & 1.3
There are several potential targets for therapeutic intervention
for both pathways (i.e., BRAF and MEK for the MAPK pathway,
and PI3K, AKT, and mTOR for the AKT/PI3K pathway). The
overall approach for this subtype is combination therapy using
inhibitors of each pathway. Several studies have been initiated or
are in planning for dual inhibition of these pathways (see below).
Specifically, NCT00349206 (M.D. Anderson Cancer Center) is
testing Sorafenib plus Temsirolimus, and NCT01021748 (Merck
& Astrazeneca) is testing MK2206 plus AZD6244.
Subtype 1.4 overview
Subtype 1.4 is associated with aberrations in both the MAPK
and CDK pathways, specifically activation of BRAF and over-
expression of CCND1/Cyclin D. The CDK pathway has been
suggested to contribute to metastasis of melanoma with BRAF
mutations. Curtin and colleagues showed that primary melanomas
arising from chronically sun-damages skin and mucosal sites, the
latter of which typically do not harbor BRAF and NRAS
mutations, have increased CCND1 copy number [26]. Unlike
primary melanomas, .15% of metastatic melanoma samples with
BRAF mutations exhibit amplification of CCND1. These
melanomas are resistant to BRAF inhibitors highlighting the need
for combination therapy [27].
Potential therapeutic approach for subtype 1.4
The approach to treatment of subtype 1.4 is a combination of
CDK and BRAF inhibitors. Several ongoing studies are
investigating the impact of these individual classes of drugs on
advanced melanoma, but none currently focus on both pathways
concurrently. Given the role of CCND1 amplification in resistance
to BRAF inhibitors, combination trials are likely on the horizon.
In the meantime, a potential therapeutic approach is sequential
administration of BRAF and CDK inhibitors, or perhaps even
treatment with chemotherapeutic agents to potentially inhibit
CDK/cell cycle pathways.
Subtype 2
This subtype is characterized by mutations in the c-KIT
pathway/complex, a receptor tyrosine kinase (RTK) that regulates
intracellular processes such as cell growth, division, and migration
in response to Stem Cell Factor (SCF) activity. c-KIT signal
transduction appears to be at least partly mediated through
activation of the MAPK, the AKT/PI3K, and/or the MITF
pathways [28–29]. Activating c-KIT mutations have been impli-
cated in a variety of cancers [30] starting with GIST (Gastrointes-
tinal stromal tumors) and CML (Chronic Myelogenous Leukemia).
Because of this there are both approved drugs and drugs in clinical
development that target c-KIT including Imatinib, Sunitib,
Nilotinib, and Dasatanib. Mutations in c-KIT exon 11 (L576P)
and exon 13 can be detected by targeted sequencing.
Subtype 2.1 overview
Currently 2.1 is the only subtype in this category and is
characterized by genetic aberrations in c-KIT, typically including
mutations and/or copy number increases [31]. In 2006, Bastian
and colleagues conducted a systematic study evaluating the
frequency of c-KIT aberrations in melanoma finding mutations
and/or copy number increases in 39% of mucosal, 36% of acral,
and 28% of melanomas on chronically sun-damaged skin, but not
in melanomas on skin without chronic sun damage [32]. This
finding is consistent with those of several additional studies that
have also investigated the frequency of c-KIT aberrations [33].
However most of these studies have been conducted on small
patient samples and larger numbers, as well as consecutive patient-
studies, will be needed to determine more accurate incidences of
c-KIT in various types of melanoma. c-KIT aberrations do not
seem to typically overlap with mutations such as B-RAF and
NRAS even though these are amongst the most common
mutations in melanoma [32].
Potential therapeutic approach for subtype 2.1
The general treatment strategy for subtype 2.1 is c-KIT
inhibitors, several of which are either approved or in development
(see below). In the early 2000 s, three Phase II clinical trials failed
to show significant responsiveness of metastatic melanoma to
Gleevec treatment, however patients in these trials were not
selected on the basis of their c-KIT status. The only responder in
this trial had very high KIT protein expression, supporting the
hypothesis that c-KIT aberrant melanomas are responsive to c-
KIT inhibitors such as Gleevec.
Additional support has come from individual case studies:
N A patient with anal mucosal melanoma and metastases to
lymph nodes harbored an amplified KIT K642E mutation.
A Melanoma Molecular Disease Model
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was achieved after a dose-escalation Gleevec regimen [34].
N A patient with KIT V560D mutant anal melanoma with
isolated lung metastases had a complete response to a
combination of Nexavar and Temozolomide [35].
N A patient with with a KIT PYDHKWE duplication rectal
melanoma demonstrated a significant clinical response after 4
weeks of Gleevec treatment [36].
N A patient with a KIT L576P vaginal mucosal melanoma and
extensive metastases to lymph nodes demonstrated a dramatic
reduction in metabolic activity with Sprycel [37].
There are many additional clinical trials that are testing efficacy
of c-KIT inhibitors in melanoma (see Table S1). While final results
from these studies are forthcoming, some interim results have been
insightful. Results of an ongoing, Phase II trial of Gleevec therapy
for metastatic melanoma patients were presented at ASCO’s 2009
conference [38]. All patients in this trial had specific mutations in
c-KIT and/or amplification of c-KIT as well as acral, mucosal, or
chronic sun damaged melanoma (which often demonstrate c-KIT
aberrations). Of twelve subjects, two had complete responses, two
had partial responses, six had stable disease, and two progressed.
Both of the complete responders had mutations as well as
amplification. The differential responses were correlated with
distinct c-KIT aberrations, suggesting that responsiveness to c-
KIT inhibitors is genotype-specific (see Table 3).
Interim results of another multi-institutional Phase II clinical
trial were presented at the International Melanoma Congress in
November 2009 [39]. This trial evaluated the efficacy of Gleevec
on patients with mucosal, acral/lentiginous, or chronically sun-
damaged skin. None of the 10 patients with wild-type/amplified
KIT showed a clinical response, although two of these patients had
stable disease for 6–7 months. Five of 10 patients with KIT
mutations demonstrated a partial response to imatinib treatment,
three of whom also had amplified KIT.
Subtype 3
Subtype 3 harbors mutations in the G proteins, GNAQ and
GNA11.
Subtype 3.1 overview
Subtype 3.1 is characterized by a mutation in the GNAQ gene
that affects codon 209 and which could drive constitutive activity
of the MAPK pathway. GNAQ encodes the alpha subunit of a q
class of heterotrimeric GTP binding proteins (Gq) that enable
signaling from the cell surface to the protein kinase C (PKC)
protein and finally the MAPK pathway. Mutations in GNAQ have
been found in .85 of blue naevi, .50% of malignant blue naevi
and ,50% of ocular melanoma of the uvea [39]. While GNAQ is
primarily viewed as relevant to uveal melanoma, anecdotal reports
have found mutations in this gene in non-uveal melanoma patients
as well. Studies so far have not identified other molecular
aberrations that segregate with GNAQ.
Subtype 3.2 overview
Subtype 3.2 is characterized by a mutation in the GNA11 gene
that affects codon 209 and which, like GNAQ, could drive
constitutive activity of the MAPK pathway. GNA11 was identified
in a forward genetic screen in mice, along with GNAQ, looking for
aberrant pigmentation symptoms in melanocytes. Like GNAQ,
GNA11 encodes for the alpha subunit of a q class of heterotrimeric
GTP binding proteins (Gq). Also like GNAQ, although GNA11 is
primarily viewed as relevant to uveal melanoma, anecdotal reports
have found mutations in this gene in non-uveal melanoma patients
[40–41]. Mutations at codon 209 in GNAQ or GNAQ11 lead-
ing to constitutive activation can be detected through targeted
sequencing.
Potential therapeutic approach for subtypes 3.1 and 3.2
Several MEK inhibitors are currently in development and are
potentially relevant to treatment of these subtypes.
Subtype 4
Subtype 4 is associated with RAS gene abnormalities. Ras
proteins are small GTPases that regulate cellular behavior in
response to extracellular stimuli. Ras-regulated signal pathways
control processes such as actin cytoskeletal integrity, proliferation,
differentiation, cell adhesion, apoptosis, and cell migration via the
MAPK and AKT/PI3K pathways.
Ras has many isoforms of which NRas and KRas are the most
relevant to human cancer. These are mutated in an estimated 20–
30% of all cancers [42]. While these isoforms are functionally
similar, their roles may be tissue-specific [43]. For example, KRas
aberrations are frequently found in pancreatic cancer [44] whereas
HRas aberrations are frequently observed in bladder cancer [45].
The Q61R and Q61L NRAS mutations can be detected by
targeted sequencing.
Subtype 4.1 overview
Subtype 4.1 is characterized by mutations in NRAS, which are
observed in approximately 20% of melanomas [46,19].
Potential therapeutic approach for subtype 4.1
Despite the wide breadth of knowledge implicating Ras in tumor
initiation and promotion, Ras has not been successfully drugged.
Two approaches have been considered. The first approach involves
blocking farnesylation. However, a small clinical trial witha farnesyl
transferase inhibitor failed to demonstrate efficacy in a melanoma
cohort that was not selected based on NRas status [47]. A more
stringently selected cohort may have been more responsive.
The second approach involves concurrently targeting down-
stream pathways such as the MAPK and AKT/PI3K pathways.
This has proven efficacious in preclinical models [48], and will be
tested clinically by Merck and Astrazeneca in the near future
(NCT01021748: MK2206 and AZD6244 for solid tumors).
Subtype 5
This subtype is characterized by abnormalities in the melano-
cyte development and survival pathway. Within this pathway the
melanocyte transcription factor MITF (Microphthalmia-associated
transcription factor) regulates development, differentiation, and
Table 3. Treatment outcomes related to specific c-KIT
aberrations.
No. of
patients
Treatment
outcome c-KIT aberration
2 Complete
response
L576P exon 11 mutation & amplification
2 Partial response L576P exon 11 mutation & exon 13 mutations
6 Stable disease Exon 13 mutations with or without amplification
2 No response Mutations known to cause resistance to Gleevec
in GIST
doi:10.1371/journal.pone.0018257.t003
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MAPK pathway as well as the cAMP pathway and leads to
transcription of genes involved in pigmentation (such as TYR and
DCT) as well as cell cycle progression and survival. For example,
MITF may contribute to increased Bcl-2 activity [51] and drive
transcription of the cell cycle regulator, CDK2.
Subtype 5.1 overview
This subtype is characterized by aberrations in MITF. A
genome-wide analysis of copy number alterations in cancer
identified MITF as an amplified locus in melanoma. Furthermore,
MITF amplification correlated with decreased overall patient
survival. In addition, MITF amplification was associated with
increased resistance to chemotherapy [52] suggesting that it may
serve as a good target for therapeutic intervention. Copy number
aberrations in MIFT can be detected by commercial tests.
Potential therapeutic approach for subtype 5.1
While MITF does not exhibit druggable activity, its expression
was shown to be attenuated by multiple histone deacetylase
(HDAC)-inhibitor drugs [53]. Building on this work, a clinical trial
has recently begun accrual to evaluate efficacy of the HDAC
inhibitor LBH589 on melanoma (NCT01065467- also see below).
This study will also determine whether LBH589 effectively down
regulates MITF in biopsy specimens of treated metastatic mela-
noma patients.
Subtype 6
This subtype is associated with abnormalities in the AKT/PI3K
signaling pathway which plays a pivotal role in modulating cellular
functions such as proliferation, growth, survival, and metabolism
in response to extracellular cues mediated by cell surface recep-
tors and G-proteins. In the absence of external stimuli, PTEN
generates the messenger phospholipid PIP2 by dephosphorylating
PIP3. PIP2 cannot stimulate phosphorylation of the PI3K protein,
which in turn maintains suppression of cell growth and division.
The balance between PIP2 and PIP3 is maintained by PTEN
(Phosphatase and TENsin homolog) and PI3K, a kinase that
converts PIP2 into PIP3. Upon growth factor stimulation, PI3K is
activated which leads to increase in PIP3 levels. PIP3 binds to Akt
and then translocates to the plasma membrane where Akt is
activated by phosphorylation. Activated Akt phosphorylates its
substrates including the serine/threonine kinase mTOR which
then phosphorylates S6 kinases (S6K) and inhibits 4E-BP, leading
to increased protein translation as well as other targets that
regulate cell division and apoptosis [54]. Relevant aberrations in
PTEN and PI3K levels can be detected by IHC. Aberrations in
AKT levels can be detected by copy number analysis.
Subtype 6.1 overview
Subtype 6.1 harbors aberrations in PTEN, a lipid phosphatase
that negatively regulates growth through the AKT/PI3K pathway.
As described above, PTEN acts antagonistically with the lipid
kinase, PI3K, to tip the balance between two signaling molecules,
PIP2 and PIP3. Upon growth factor stimulation, PI3K is
activated, increasing PIP3 levels which drives phosphorylation of
AKT and downstream processes such as higher protein transla-
tion, cell division and reduced apoptosis.
Inactivation of PTEN is associated with a variety of cancers
including glioblastoma, melanoma, and carcinomas of prostate,
breast, and endometrial origins. Loss of (or reduced) PTEN
protein is observed by immunohistochemistry (IHC) in 20–40%
of melanoma tumor samples [55–57,19]. Somatic PTEN point
mutations and homozygous deletions are rare [58]. Consistent
with its role in the AKT/PI3K pathway, 82% of specimens with
PTEN loss had measurable increases in expression of pAKT [59].
PTEN dysregulation often occurs in conjunction with mutations
in BRAF and this combination has been classified as subtype 1.2.
The relative frequency of these subtypes is not clear though we
hope to learn more based on patient reports and research studies.
Subtype 6.1 specifically deals with dysregulation of PTEN in the
absence of BRAF mutations which leads us to consider AKT/
PI3K inhibitors as potential therapies for this subtype.
Subtype 6.2 overview
Subtype 6.2 consists of aberrations in Akt, a protein kinase of
the Protein Kinase B (PKB) family that plays a central role in
coordinating cellular behavior with signals from a variety of
extracellular pathways. As described above, Akt is regulated by the
lipid signaling molecular PIP3, whose levels are determined by the
interplay between PTEN and PI3K. Humans have three AKT
genes: Akt1, Akt2, and Akt3 [60]. Akt1 is involved in apoptosis
and protein synthesis, Akt2 is involved in glucose metabolism and
Akt3 may be involved in several processes.
Akt has been implicated in many cancers including melanoma.
More than 70% of primary and metastatic melanomas exhibit
higher Akt activity as monitored by immunostaining against the
Serine-473 residue of Akt [61,56]. Additionally, the 1q43–44
genomic region that contains Akt3 is often amplified [62].
AKT dysregulation has been observed to occur in conjunction
with mutations in BRAF, and this combination has been classified
as subtype 1.3. The relative frequency of these subtypes is not
clear, though we hope to learn more based on patient reports and
research studies. Subtype 6.2 specifically deals with dysregula-
tion of Akt in the absence of BRAF mutations, which leads us
to consider AKT/PI3K inhibitors as potential therapies for this
subtype.
Subtype 6.3 overview
Subtype 6.3 is characterized by aberrations in PI3K, a lipid
kinases that regulates growth through the AKT/PI3K pathway.
As described above, PI3K acts antagonistically with the lipid
phosphatase, PTEN, to tip the balance between two signaling
molecules, PIP2 and PIP3. Upon growth factor stimulation, PI3K
is activated which increases PIP3 levels and promotes phosphor-
ylation of AKT and downstream processes such as increased
protein translation, cell division and reduced apoptosis.
The PI3K protein family is divided into three classes and several
subclasses based on primary structure, regulation, and in vitro lipid
substrate specificity. Of these, Class Ia is the best understood,
partly because of its role in cancer. These proteins are composed
of a catalytic subunit (p110) and a regulatory subunit (p85).
PI3K expression is higher in malignant melanomas (as com-
pared to blue nevi) and is correlated with a worse prognosis [63].
In contrast, activating mutations found in ,1% of primary
melanomas and comparative genomic hybridization did not reveal
genomic amplification [59].
Potential therapeutic approach for subtypes 6.1, 6.2 and
6.3
There are three potential targets for therapeutic intervention
against this pathway: AKT, PI3K and mTOR. Both subtypes 6.1
and 6.3 could potentially be treated with all three classes of drugs,
but subtype 6.2 is not expected to respond to PI3K inhibitors.
There are several drugs in clinical development targeting all three,
and a few drugs against mTOR that are currently approved for
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anxiously awaited though they may be mixed because none of
them are focused exclusively on patients with PTEN aberrations
(or aberrations in the AKT/PI3K pathway). Even in a selected
patient population results may be mixed. This was observed in a
Phase I clinical trial investigating the impact of the mTOR
inhibitor, Rapamycin, in PTEN-deficient glioblastoma; the drug
proved effective in suppressing disease progression in some
patients but appeared to accelerated disease in others [64].
Pending trial results, a few case reports have emerged suggesting
efficacy of Rapamycin in conjunction with the chemotherapeutic
drugs carboplatin and paclitaxel in melanoma [65]. This theme
has also been observed across several cancers including ovarian,
breast, and pancreatic carcinomas and points to a universal role of
this pathway in driving chemoresistance [66]. Several clinical trials
listed below are investigating specific combinations of mTOR
inhibitors and chemotherapy drugs in the treatment of melanoma.
Subtype 7
This subtype is characterized by aberrations in the G1/S
Cyclin/CDK pathways. CDKs belong to a family of protein
kinases that control cellular proliferation by phosophorylating
proteins involved in the regulation and mechanics of processes
such as growth, DNA replication, and mitosis. The cyclin proteins
are regulatory subunits that bind and activate the CDKs that bear
catalytic kinase activity.
Several distinct types of cyclins and CDKs have been identified
and appear to drive distinct stages of the cell cycle. For example,
Cyclin D/CDK4 complexes drive passage from the pre-replicative
(G1) to the DNA duplication (S) phase, the Cyclin E/CDK2
complexes drive DNA duplication, and the Cyclin B/CDK1
complexes drive entry into mitosis. In addition to the cyclins, the
cell cycle is influenced by numerous inhibitors (such as p16INK4)
and activators that ensure mutual dependence of DNA replication
and mitosis as well as coupling to extracellular signals [67].
Targeted sequencing and Comparative Genomic Hybridization
(CGH) assays are available for ARF/INK4A, copy number
analysis for CDK4, and IHC for CCND1/Cyclin D.
Subtype 7.1 overview
This subtype is associated with aberrations in ARF/INK4A, which
encodes for p16INK4, a cell cycle regulator, and p14ARF, a
regulator of the p53 pathway (http://www.ncbi.nlm.nih.gov/gene/
1029). p16INK4 binds to and inhibits CyclinD & CDK4/6 com-
plexes which suppresses progression from G1to S transition. p14ARF
binds to, and inhibits, MDM2 which leads to stabilization of p53.
The ARF/INK4A gene is a key susceptibility locus for familial
melanoma [68], and is also often somatically mutated in melanoma.
ARF/INK4A mutations in melanoma typically occur in the
p16INK4 gene either alone or in combination with p14ARF,
suggesting that p16INK4 is the relevant tumor suppressor.
p16INK4 is deleted in approximately 50% of melanomas and
inactivated by point mutations in about 10% [69]. In addition, this
gene is often transcriptionally silenced by promoter hypermethyla-
tion [69–70]. Reduced p16INK4 levels correlate with disease
progression [71–72] and poor prognosis [70]. However, some
families harbor mutations only in p14ARF suggesting a role in
melanomaprogression[74–75].Mousestudiesindicatethateitheris
sufficient for melanoma predisposition and that they might, in fact,
cooperate to drive disease progression [76–77].
Subtype 7.2 overview
This subtype is characterized by aberrations in CDK4, which
drives passage from G1 to S phase in complex with Cyclin D by
phosphorylating and inactivating the retinoblastoma protein (RB)
inhibitor. CDK4 amplification is relatively common in acral and
mucosal melanomas [26,78]. Additionally, a substitution of
Cysteine for Arginine at the 24th codon of CDK4 is observed in
a small percentage of melanoma-prone families [79]. CCND1/
Cyclin D amplification is observed in approximately 4% of
melanomas [26,78,80].
Subtype 7.3 overview
Subtype 7.3 is characterized by aberrations in Cyclin D, which
drives passage from G1 to S in complex with CDK4 and CDK6.
Cyclin D is commonly found to be aberrant in cancer in terms of
mutation, amplification, and/or overexpression. Overexpression
has been observed in mantle cell lymphoma, non-small cell lung
cancer and carcinomas of breast, head and neck, and esophagus.
Amplification of the Cyclin D gene has been observed in tumors
such as head and neck carcinomas, pituitary tumors, esophageal
squamous cell carcinoma, and breast cancer [81].
In melanoma, genomic amplifications of Cyclin D are primarily
found in acral lentiginous melanoma (,44%), and to a lesser
degree in other types (11% for lentigo maligna and 6% for
superficial spreading melanoma) [82]. Antisense-mediated knock-
down of CCND1 triggers apoptosis in vitro and shrinkage of
xenografts in mice [82], suggesting that Cyclin D plays a role in
melanoma tumorigenesis and so may be a good target for
therapeutic intervention.
Potential therapeutic approach for subtype 7
Any therapeutic strategy for subtype 7.1 will likely depend on
the specific mutations within individual tumors. Tumors with
mutations that only affect p16INK4 could potentially be addressed
with inhibitors of CDK4/6. There are currently no validated
therapeutic options for tumors with only p14ARF mutations. For
subtypes 7.2 and 7.3, several CDK4 inhibitors are currently in
development for a variety of cancer types. UCN-01 is currently
involved in ongoing Phase II trials for metastatic melanoma.
Subtype 8
This subtype is associated with aberrations in the p53-regulated
intrinsic cell death pathway. This pathway is initiated by p53 in
response to cellular stress such as growth factor deprivation,
hypoxia, cell detachment, or DNA damage [83] and results in the
activation of the Bcl-2 family of proapoptotic genes. The Bcl-2
pathway contains activators and inhibitors of apoptosis that
together influence the fate of a cell. IHC can detect aberrations in
the level of BCL-2, and targeted sequencing can detect P53
mutations.
Subtype 8.1 overview
Subtype 8.1 is characterized by aberrations in Bcl-2, a key
inhibitor of cell apoptosis. The Bcl-2 family of proteins contains
both pro- and anti-apoptotic members that regulate apoptosis via a
delicate balance [84]. The Bcl-2 pathway is activated via p53 in
response to cellular stress such as growth factor deprivation,
hypoxia, cell detachment, or DNA damage. Several lines of
evidence point to a key role of this pathway in melanoma
pathogenesis: 1. BCL-2 is overexpressed in melanoma [85–86]:
Factors including NRas [87] and MITF may also contribute to
increased Bcl-2 activity [51]. 2. Anti-sense suppression of Bcl-2
leads to decreased melanoma cell survival and increased sensitivity
to chemotherapy [88–89,51]. 3. Bcl-2 overexpression reduced
apoptosis and sensitivity of melanoma cells to pro-apoptotic
stimuli.
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Subtype 8.2 is characterized by mutations in the tumor
suppressor, p53. p53 is mutated in greater than half of all human
cancers but in only about 10% of melanomas [90]. However,
studies in mice and in vitro studies indicate that the p53 pathway
contributes to melanoma. In particular, it appears that the p53
pathway can be suppressed by directly inactivating p53 or by
modulating the p53 inhibitor, p19ARF. Consistent with this, there
are sporadic examples of human melanoma cases with mutated
p19ARF. p53 also appears to play a role in resistance to
chemotherapy because apoptosis is considered to be the primary
mechanism by which chemotherapeutic drugs drive tumor cell
death [91]. Mutant p53 cell lines appear to be refractory to drugs
like cisplatin, vincristine and camptothecin [92–93].
Potential therapeutic approach for subtype 8
There are currently no drugs approved or in trials that could be
therapeutic for this subtype of melanoma. However several,
including YM155, ABT-737, AT-101, and TW37, are in
preclinical development. One anti-apoptotic agent, Oblimersen,
an anti-sense agent targeted at nuclear Bcl-2 has exhibited mixed
results in melanoma. Survival results from the AGENDA Phase III
trial of Oblimersen are awaited. However, lack of tumor Bcl-2
expression fails to confirm an in vivo mechanism of action [94].
Recently, results of a Phase I/II study evaluating the effect of a
combination of Oblimersen, Temozolomide, and Abraxane on
patients with advanced melanoma (NCT00518895) showed
increased overall survival as compared to the previous trial. In
addition, phenotypic changes were observed in Bcl-2 and related
family members and correlated with treatment outcomes [95].
Discussion
This paper describes a ’Molecular Disease Model’ (MDM) for
melanoma. Given the evolving state of knowledge, we anticipate
that the current model will be revised with new clinical and
scientific findings. To support the efficient use and dynamic
updating of this MDM, we have posted it in hyperlinked
‘‘semantic wiki’’ format here: http://mmdm.cancercommons.
org/smw/index.php/A_Melanoma_Molecular_Disease_Model.
We intend to regularly update this online version of the model
as new results appear in the literature.
Our goal in putting the melanoma MDM online in this way is to
facilitate the rapid distribution and updating of this important and
timely information. In addition, applications can be developed by
directly utilizing the model’s semantic content.
Supporting Information
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